Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation.

Leyva-Castillo JM, Galand C, Mashiko S, Bissonnette R, McGurk A, Ziegler SF, Dong C, McKenzie ANJ, Sarfati M, Geha RS.

J Allergy Clin Immunol. 2020 Mar 13. pii: S0091-6749(20)30334-1. doi: 10.1016/j.jaci.2020.02.026. [Epub ahead of print]

PMID:
32179159
2.

Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy.

Mashiko S, Edelmayer RM, Bi Y, Olson LM, Wetter JB, Wang J, Maari C, Saint-Cyr Proulx E, Kaimal V, Li X, Salte K, Garcet S, Kannan AK, Huang SM, Cao X, Liu Z, Krueger JG, Sarfati M, Bissonnette R, Smith KM.

J Invest Dermatol. 2019 Nov 9. pii: S0022-202X(19)33391-3. doi: 10.1016/j.jid.2019.09.027. [Epub ahead of print]

PMID:
31715177
3.

Ultraviolet B-induced immunosuppression is not associated with receptor activator of nuclear factor kappa B ligand upregulation in human skin.

Proulx ES, Mashiko S, Maari C, Bolduc C, Nigen S, Sarfati M, Bissonnette R.

Photodermatol Photoimmunol Photomed. 2019 Jan;35(1):47-50. doi: 10.1111/phpp.12426. Epub 2018 Oct 9. No abstract available.

PMID:
30230620
4.

Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Nagayasu K, Naito S, Sato T, Kishine K, Abe Y, Hara C, Yamada S, Mashiko S, Nagaoka I.

Oncol Lett. 2017 Nov;14(5):6045-6052. doi: 10.3892/ol.2017.6960. Epub 2017 Sep 15.

5.

Early-Life Antibiotic Exposure Causes Intestinal Dysbiosis and Exacerbates Skin and Lung Pathology in Experimental Systemic Sclerosis.

Mehta H, Goulet PO, Mashiko S, Desjardins J, Pérez G, Koenig M, Senécal JL, Constante M, Santos MM, Sarfati M.

J Invest Dermatol. 2017 Nov;137(11):2316-2325. doi: 10.1016/j.jid.2017.06.019. Epub 2017 Jul 27.

6.

Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis.

Mashiko S, Mehta H, Bissonnette R, Sarfati M.

J Dermatol Sci. 2017 Nov;88(2):167-174. doi: 10.1016/j.jdermsci.2017.07.003. Epub 2017 Jul 15.

PMID:
28743611
7.

Dabigatran aggravates topoisomerase I peptide-loaded dendritic cells-induced lung and skin fibrosis.

Mehta H, Mashiko S, Goulet PO, Desjardins J, Pérez G, Koenig M, Senécal JL, Sarfati M.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):35-39. Epub 2017 Feb 8.

PMID:
28229819
8.

Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.

Bissonnette R, Fuentes-Duculan J, Mashiko S, Li X, Bonifacio KM, Cueto I, Suárez-Fariñas M, Maari C, Bolduc C, Nigen S, Sarfati M, Krueger JG.

J Dermatol Sci. 2017 Jan;85(1):20-26. doi: 10.1016/j.jdermsci.2016.09.019. Epub 2016 Sep 29.

PMID:
27743912
9.

Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.

Jack C, Mashiko S, Arbour N, Bissonnette R, Sarfati M.

Br J Dermatol. 2017 Jul;177(1):267-270. doi: 10.1111/bjd.15029. Epub 2017 Jun 6. No abstract available.

PMID:
27599204
10.

Characteristic responses of a phospholipid molecular layer to polyols.

Nakata S, Deguchi A, Seki Y, Furuta M, Fukuhara K, Nishihara S, Inoue K, Kumazawa N, Mashiko S, Fujihira S, Goto M, Denda M.

Colloids Surf B Biointerfaces. 2015 Dec 1;136:594-9. doi: 10.1016/j.colsurfb.2015.09.035. Epub 2015 Sep 25.

PMID:
26454550
11.

Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis.

Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M.

J Allergy Clin Immunol. 2015 Aug;136(2):351-9.e1. doi: 10.1016/j.jaci.2015.01.033. Epub 2015 Mar 16.

PMID:
25792465
12.

Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.

Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata T, Yaegashi N.

Cancer Biol Ther. 2015;16(2):253-60. doi: 10.1080/15384047.2014.1001271.

13.

Mechanism underlying the transient increase of serum iron during FOLFOX/FOLFIRI therapy.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Sato T, Kishine K, Futagawa S, Mashiko S, Nagaoka I.

Mol Clin Oncol. 2014 Nov;2(6):968-972. Epub 2014 Aug 11.

14.

Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Shibata H, Sato T, Kishine K, Seo S, Okubo S, Futagawa S, Mashiko S, Nagaoka I.

Mol Clin Oncol. 2013 Sep;1(5):805-810. Epub 2013 May 30.

15.

Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I.

Oncol Lett. 2012 Oct;4(4):621-624. Epub 2012 Jul 25.

16.

Induction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53.

Yasuda K, Kato S, Sakamoto Y, Watanabe G, Mashiko S, Sato A, Kakudo Y, Ishioka C.

Oncol Lett. 2012 May;3(5):978-982. Epub 2012 Feb 29.

17.

Good response to leucovorin and fluorouracil plus oxaliplatin and cetuximab therapy in a patient with metastatic ascending colon cancer harboring a KRAS p.G13D mutation.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Ookubo S, Futagawa S, Orikasa H, Mashiko S, Nagaoka I.

Oncol Lett. 2012 Feb;3(2):269-272. Epub 2011 Nov 30.

18.

Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies.

Mashiko S, Nagaoka I, Kitajima M, Watanabe T, Nishimura K, Futagawa S, Ochiai T.

Exp Ther Med. 2010 May;1(3):507-511. Epub 2010 May 1.

19.

Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice.

Ito M, Ishihara A, Gomori A, Egashira S, Matsushita H, Mashiko S, Ito J, Ito M, Nakase K, Haga Y, Iwaasa H, Suzuki T, Ohtake N, Moriya M, Sato N, MacNeil DJ, Takenaga N, Tokita S, Kanatani A.

Eur J Pharmacol. 2009 Dec 10;624(1-3):77-83. doi: 10.1016/j.ejphar.2009.10.004. Epub 2009 Oct 18.

PMID:
19836369
20.

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.

Moriya R, Shirakura T, Ito J, Mashiko S, Seo T.

Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1358-65. doi: 10.1152/ajpendo.00412.2009. Epub 2009 Oct 6.

21.

Modulation of neuropeptide Y receptors for the treatment of obesity.

Sato N, Ogino Y, Mashiko S, Ando M.

Expert Opin Ther Pat. 2009 Oct;19(10):1401-15. doi: 10.1517/13543770903251722. Review.

PMID:
19743896
22.

Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.

Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A.

Eur J Pharmacol. 2009 Aug 1;615(1-3):113-7. doi: 10.1016/j.ejphar.2009.05.018. Epub 2009 May 29.

PMID:
19482021
23.

Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.

Sato N, Ando M, Ishikawa S, Jitsuoka M, Nagai K, Takahashi H, Sakuraba A, Tsuge H, Kitazawa H, Iwaasa H, Mashiko S, Gomori A, Moriya R, Fujino N, Ohe T, Ishihara A, Kanatani A, Fukami T.

J Med Chem. 2009 May 28;52(10):3385-96. doi: 10.1021/jm900110t.

PMID:
19459652
24.

Evaluation of the individual 50% inhibitory area under the concentration curve of 5-fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer.

Ochiai T, Nishimura K, Watanabe T, Kitajima M, Tsuji M, Nakatani A, Nakayama N, Marusasa T, Mashiko S, Nagaoka I, Futagawa S.

Mol Med Rep. 2009 May-Jun;2(3):405-9. doi: 10.3892/mmr_00000113.

PMID:
21475842
25.

Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.

Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A.

Peptides. 2009 Jul;30(7):1318-22. doi: 10.1016/j.peptides.2009.04.006. Epub 2009 Apr 23.

PMID:
19394383
26.

Chronic intracerebroventricular infusion of nociceptin/orphanin FQ produces body weight gain by affecting both feeding and energy metabolism in mice.

Matsushita H, Ishihara A, Mashiko S, Tanaka T, Kanno T, Iwaasa H, Ohta H, Kanatani A.

Endocrinology. 2009 Jun;150(6):2668-73. doi: 10.1210/en.2008-1515. Epub 2009 Feb 5.

PMID:
19196798
27.

Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.

Mashiko S, Ishihara A, Iwaasa H, Moriya R, Kitazawa H, Mitobe Y, Ito J, Gomori A, Matsushita H, Takahashi T, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A.

Obesity (Silver Spring). 2008 Jul;16(7):1510-5. doi: 10.1038/oby.2008.223. Epub 2008 Apr 10.

28.

Long-term administration of a low-molecular-weight heparin contributed to successful treatment in a patient with primary mediastinal large B-cell lymphoma and venous thromboembolism.

Mori A, Ibata M, Mashiko S, Tsutsumi Y, Masauzi N, Hashino S, Morioka M, Asaka M, Imamura M.

Clin Appl Thromb Hemost. 2008 Oct;14(4):468-71. doi: 10.1177/1076029607313623. Epub 2008 Feb 4.

PMID:
18252727
29.

Chimerism and T-cell receptor repertoire analysis after unrelated cord blood transplantation with a reduced-intensity conditioning regimen following autologous stem cell transplantation for multiple myeloma.

Toubai T, Hirate D, Shono Y, Ota S, Ibata M, Mashiko S, Sugita J, Shigematsu A, Miura Y, Kato N, Umehara S, Kahata K, Tsutsumi Y, Iwao N, Toyoshima N, Tanaka J, Asaka M, Imamura M.

Int J Lab Hematol. 2008 Feb;30(1):75-81. doi: 10.1111/j.1751-553X.2007.00903.x.

PMID:
18190473
30.

Photochemical stability of encapsulated laser dyes in dendritic nanoboxes against singlet oxygen.

Otomo A, Otomo S, Yokoyama S, Mashiko S.

Opt Lett. 2002 Jun 1;27(11):891-3.

PMID:
18026314
31.

Blockade of MCH1 receptor signalling ameliorates obesity and related hepatic steatosis in ovariectomized mice.

Gomori A, Ishihara A, Ito M, Matsushita H, Ito M, Mashiko S, Iwaasa H, Matsuda M, Bednarek MA, Qian S, Macneil DJ, Kanatani A.

Br J Pharmacol. 2007 Jul;151(6):900-8. Epub 2007 May 21.

32.

The screening of the second-site suppressor mutations of the common p53 mutants.

Otsuka K, Kato S, Kakudo Y, Mashiko S, Shibata H, Ishioka C.

Int J Cancer. 2007 Aug 1;121(3):559-66.

33.

Hyponatremia after administration of conditioning regimen in myelodysplastic syndrome with empty sella after glandula pituitaria surgery.

Tsutsumi Y, Shiratori S, Nakata A, Kawamura T, Mashiko S, Ibata M, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N.

Ann Hematol. 2007 Nov;86(11):843-4. Epub 2007 Apr 6. No abstract available.

PMID:
17415566
34.

A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.

Mashiko S, Ishihara A, Iwaasa H, Sano H, Ito J, Gomori A, Oda Z, Moriya R, Matsushita H, Jitsuoka M, Okamoto O, MacNeil DJ, Van der Ploeg LH, Fukami T, Kanatani A.

Mol Pharmacol. 2007 Feb;71(2):602-8. Epub 2006 Nov 14. Erratum in: Mol Pharmacol. 2007 May;71(5):1444.

PMID:
17105869
35.

Syndrome of inappropriate secretion of ADH after administration of intrathecal chemotherapy in acute promyelocytic leukemia with empty sella of pituitary gland.

Tsutsumi Y, Kawamura T, Shiratori S, Mashiko S, Ibata M, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N.

Ann Hematol. 2007 Feb;86(2):149-50. Epub 2006 Oct 10. No abstract available.

PMID:
17031687
36.

Surface pressure induced charge transfer between fullerene and tetrathiafulvalene derivative in Langmuir-Blodgett films.

Nakamura T, Miyata H, Wakahara K, Akutagawa T, Hasegawa T, Hasegawa H, Mashiko S, Christensen CA, Becher J.

J Nanosci Nanotechnol. 2006 Jun;6(6):1833-7.

PMID:
17025095
37.

Abnormal expansion of naïve B lymphocytes after unrelated cord blood transplantation--a case report.

Shono Y, Toubai T, Ota S, Ibata M, Mashiko S, Hirate D, Miura Y, Umehara S, Toyoshima N, Tanaka J, Asaka M, Imamura M.

Clin Lab Haematol. 2006 Oct;28(5):351-4.

38.

Deposition of thermally unstable molecules with the spray-jet technique on Au(111) surface.

Suzuki H, Yamada T, Kamikado T, Okuno Y, Mashiko S.

J Phys Chem B. 2005 Jul 14;109(27):13296-300.

PMID:
16852658
39.
40.

Leukoencephalopathy with cerebral hemorrhage following acute pancreatitis due to tacrolimus in a case of allogeneic peripheral blood stem cell transplantation.

Tsutsumi Y, Kanamori H, Mashiko S, Yamato H, Ibata M, Ehira N, Kawamura T, Umehara S, Obara S, Mori A, Ogura N, Tanaka J, Asaka M, Imamura M, Masauzi N.

Leuk Lymphoma. 2006 May;47(5):943-7. No abstract available.

PMID:
16753888
41.

Loss of heterozygosity in yeast can occur by ultraviolet irradiation during the S phase of the cell cycle.

Daigaku Y, Mashiko S, Mishiba K, Yamamura S, Ui A, Enomoto T, Yamamoto K.

Mutat Res. 2006 Aug 30;600(1-2):177-83. Epub 2006 Jun 5.

PMID:
16737721
42.

A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.

Ishihara A, Kanatani A, Mashiko S, Tanaka T, Hidaka M, Gomori A, Iwaasa H, Murai N, Egashira S, Murai T, Mitobe Y, Matsushita H, Okamoto O, Sato N, Jitsuoka M, Fukuroda T, Ohe T, Guan X, MacNeil DJ, Van der Ploeg LH, Nishikibe M, Ishii Y, Ihara M, Fukami T.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):7154-8. Epub 2006 Apr 24.

43.

Molecularly assembled nanostructures of a redox-active organogelator.

Akutagawa T, Kakiuchi K, Hasegawa T, Noro S, Nakamura T, Hasegawa H, Mashiko S, Becher J.

Angew Chem Int Ed Engl. 2005 Nov 11;44(44):7283-7. No abstract available.

PMID:
16229035
44.

Successful reduced-intensity stem cell transplantation (RIST) for a patient with malignant lymphoma and an ileostomy.

Toubai T, Tanaka J, Ota S, Mori A, Ibata M, Shono Y, Mashiko S, Sugita J, Miura Y, Kato N, Umehara S, Kahata K, Toyoshima N, Asaka M, Imamura M.

Intern Med. 2005 May;44(5):476-9.

45.

Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.

Mashiko S, Ishihara A, Gomori A, Moriya R, Ito M, Iwaasa H, Matsuda M, Feng Y, Shen Z, Marsh DJ, Bednarek MA, MacNeil DJ, Kanatani A.

Endocrinology. 2005 Jul;146(7):3080-6. Epub 2005 Apr 7.

PMID:
15817671
46.

Conformation selective assembly of carboxyphenyl substituted porphyrins on Au (111).

Yokoyama T, Kamikado T, Yokoyama S, Mashiko S.

J Chem Phys. 2004 Dec 15;121(23):11993-7.

PMID:
15634161
47.

Long-term follow-up of a patient with idiopathic myelofibrosis associated with chromosome 11 and 13 abnormalities.

Toubai T, Tanaka J, Higa T, Ota S, Ibata M, Shono Y, Mashiko S, Miura Y, Umehara S, Kahata K, Toyoshima N, Morioka M, Asaka M, Kasai M, Imamura M.

Am J Hematol. 2005 Jan;78(1):67-70.

48.

Vibrationally resolved fluorescence from organic molecules near metal surfaces in a scanning tunneling microscope.

Dong ZC, Guo XL, Trifonov AS, Dorozhkin PS, Miki K, Kimura K, Yokoyama S, Mashiko S.

Phys Rev Lett. 2004 Feb 27;92(8):086801. Epub 2004 Feb 24.

PMID:
14995803
49.

Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice.

Takahashi K, Mizuarai S, Araki H, Mashiko S, Ishihara A, Kanatani A, Itadani H, Kotani H.

J Biol Chem. 2003 Nov 21;278(47):46654-60. Epub 2003 Sep 16.

50.

Supplemental Content

Loading ...
Support Center